Seismic Therapeutic

seismictx.com →

-56%

est. 2Y upside i

HealthcareSeries B

Rank

#1741

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Seismic Therapeutic presents a high-risk, moderate-upside equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (21%)+300%

Seismic's lead programs, S-1117 and S-4321, demonstrate exceptionally strong Phase 1 and early Phase 2 clinical data, validating the IMPACT platform's ability to generate superior biologics. This leads to a major partnership with a large pharmaceutical company or an accelerated IPO at a valuation of $3 billion, a 3x increase from the current estimated $750M.

Base (42%)+50%

Seismic successfully advances its lead programs through Phase 1 and into Phase 2, showing promising but not groundbreaking results. The company secures additional funding rounds at a moderate step-up, reaching a valuation of $1.125 billion, a 1.5x increase, reflecting steady progress in a competitive market but requiring further significant investment before a major liquidity event.

Bear (37%)-75%

Clinical trials face delays or show mixed results, or a competitor's AI-driven therapy achieves a significant breakthrough, diminishing Seismic's competitive edge. The company struggles to raise subsequent funding at an attractive valuation, leading to a down round or a modest acquisition at a valuation of $300 million or less, significantly eroding common stock value due to the existing $222 million in liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $222 million in liquidation preferences ahead of common stock, representing 29.6% of the estimated $750 million valuation.

Dilution Risk

high

As a clinical-stage biotech, Seismic will require substantial additional funding rounds to complete clinical trials, leading to significant future dilution.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for Seismic Therapeutic shares.

Questions to Ask at the Interview

Strategic questions based on Seismic Therapeutic's data — designed to show you've done your homework.

  • 1

    “With several other well-funded companies also leveraging AI for immunology drug discovery (e.g., DeepLife, Athos Therapeutics, Immunai), how does Seismic's IMPACT platform differentiate itself beyond the initial Phase 1 data, and what specific competitive advantages do you foresee in later-stage clinical development?”

  • 2

    “Given the very high capital intensity of biotech and the need for significant future funding rounds, how is Seismic planning to manage dilution for employees holding common stock or options, and what are the company's long-term financing strategies beyond Series B?”

  • 3

    “The company has dosed its first cohort in a Phase 1 trial for S-4321. What are the key milestones and data readouts expected over the next 18-24 months that would significantly de-risk the pipeline and potentially accelerate a liquidity event?”

Community

Valuation Sentiment

Our model estimates -56% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.